Group 1 - Cooper Investors Global Equities Fund reported a return of -0.04% in Q3 2025, underperforming the MSCI AC World Index Net Divs which returned 6.42% in Australian Dollars [1] - The fund achieved a rolling 12-month return of 18.0% post fees, indicating a strong performance over the longer term despite short-term fluctuations [1] - The fund's portfolio structure is primarily not correlated with the index, suggesting that its returns are expected to diverge from index movements [1] Group 2 - GE HealthCare Technologies Inc. (NASDAQ:GEHC) was highlighted as a key stock in the fund's portfolio, with a one-month return of 16.30% and a 52-week gain of 4.35% [2] - As of December 05, 2025, GE HealthCare Technologies Inc. closed at $85.46 per share, with a market capitalization of $39.018 billion [2] - The company, which manufactures and markets medical devices, was added to the portfolio in late 2023 following its spin-off from GE, allowing for a focused management approach to drive value creation [3]

Group 1 - The current favorable conditions have led companies to rush into the bond market for cheap merger financing, resulting in a global M&A financing scale of $113 billion this quarter, the largest in four years and one of the highest on record [1][4] - Merck and GE Healthcare raised a combined $9.25 billion in a single day for acquisitions announced two weeks prior, indicating strong credit sentiment as corporate spreads approach historical lows [1][4] - The pharmaceutical sector has been particularly active, with Novo Nordisk raising €4 billion for the acquisition of Akero Therapeutics and Pfizer selling $6 billion in bonds for the acquisition of Metsera [4] Group 2 - Demand for bonds has been so strong that borrowers do not need to pay a premium even when including clauses for debt buybacks if mergers are not completed on time, reducing the risk of accumulating additional debt if deals fail [4][5] - Companies like Magnum have included clauses in their bonds allowing for early repayment if their spin-off does not finalize by mid-next year, indicating a strategic approach to financing [5] - The return of M&A activity is being strongly felt, with banks underwriting approximately $65 billion in debt related to leveraged buyouts for 2026, and expectations for a broader recovery in M&A activity in 2026 [6]

Summary of the 2026 Hospital Outlook Survey Industry Overview - The survey focuses on the US healthcare industry, specifically the hospital sector, and provides insights into capital expenditures, utilization trends, and the impact of macroeconomic factors on hospital operations [1][2]. Key Insights Utilization Trends - **Utilization Growth Expectations**: 52% of hospital executives anticipate utilization growth in 2026 to be above 2025 levels, a decrease from 55% in the previous year [7][19]. - **Outpatient vs. Inpatient**: 56% expect outpatient utilization growth to exceed 2025 levels, while 41% expect inpatient utilization growth to increase, up from 34% last year [11][19]. - **Elective Procedures**: 54% expect elective procedures to grow above or in line with 2025 levels, down from 64% last year [16][19]. Capital Expenditures (CapEx) - **CapEx Growth**: Hospital capital spending is projected to increase by 4.1% in 2026, consistent with the 4.0% growth reported in 2025 [7][45]. - **Investment Priorities**: Hospitals are likely to increase spending on bedside patient monitoring, bedside pumps, and operating room (OR) suite equipment [16][45]. - **Impact of OBBBA**: The One Big Beautiful Bill Act (OBBBA) may lead to conservative spending due to anticipated reimbursement pressures [49][46]. Robotics and Technology - **Robotic Systems**: 96% of hospitals currently utilize surgical robotic systems, with Intuitive Surgical maintaining a leading position in soft-tissue robotics [90][91]. - **Orthopedic Robotics Demand**: 49% of respondents expect to purchase orthopedic robotic systems, with Stryker's MAKO being the most favored option [7][8]. - **IT Investments**: Hospitals are prioritizing IT investments, particularly in AI (66% expect to increase spending) and cybersecurity (65%) [80][81]. Value-Based Care (VBC) - **Revenue Tied to VBC**: The average revenue tied to VBC arrangements is approximately 19%, down from 22% last year, although interest in establishing VBC partnerships has increased [34][35]. Challenges and Concerns - **Reimbursement Pressure**: 34% of executives cite reimbursement pressure as the biggest challenge for hospitals in the coming year, an increase from 25% last year [58][59]. - **Labor Costs**: Labor cost inflation remains a significant concern, with 18% of respondents identifying it as a major challenge [58][59]. Future Outlook - **Purchasing Intentions**: Despite economic uncertainties, over 70% of hospitals plan to consider purchasing new equipment across various categories in the next two years [62][64]. - **Investment in ASCs**: 57% of respondents expect to increase investments in Ambulatory Surgery Centers (ASCs) over the next year, reflecting a shift towards outpatient care [18][19]. Additional Insights - **AI Utilization**: Hospitals are increasingly leveraging AI for tasks such as medical record analysis (56%) and clinical imaging analysis (52%), with larger hospitals showing a higher propensity to adopt these technologies [81][88]. - **Market Dynamics**: The survey indicates a stable payor mix for 2026, with commercial insurers and Medicare making up approximately 70% of the mix [12][27]. This comprehensive survey provides a detailed outlook on the hospital sector, highlighting trends in utilization, capital spending, and the evolving landscape of healthcare technology and reimbursement challenges.

Group 1: Federal Reserve and Economic Outlook - U.S. consumer sentiment is rising for the first time in five months, indicating a potential shift in economic momentum as traders prepare for Federal Reserve actions amidst concerns over central bank independence [1][2] - The bond market is anticipating a dovish bias from the Federal Reserve, with expectations of rate cuts increasing, particularly for three cuts in 2026, which are now at a 25% likelihood [3][4] - There are doubts regarding Kevin Hassett's credibility as a potential Federal Reserve chair, which could impact the committee's consensus and the overall direction of monetary policy [4][5][6] Group 2: Market Dynamics and Debt Issuance - December is projected to be one of the busiest months for debt sales, with $27 billion already sold, marking the highest amount for the first week of December since 2021 [17] - High-yield markets are seeing significant activity, with 12 borrowers raising over $12 billion, indicating a robust environment for capital raising despite economic concerns [18] - The overall net issuance for the year has decreased by nearly 10%, but significant issuance is expected in 2026, particularly driven by AI capital expenditures [21][22][23] Group 3: Investment Strategies and Opportunities - Investors are advised to be selective in their approach, focusing on companies that can leverage secular trends, particularly in technology and AI, to navigate the upcoming credit cycle [19][27] - The importance of due diligence is emphasized, especially in identifying strong collateral and appropriately priced opportunities in the evolving market landscape [32][33] - The potential for volatility in the high-yield market is acknowledged, with a focus on maintaining liquidity and being prepared for market shifts [30][34]

Core Viewpoint - Medtronic has appointed Dr. Gerald Denny as Chief Medical Officer for its Acute Care & Monitoring (ACM) business, aiming to enhance its global medical strategy and clinical support [2]. Industry Background - The acute care and patient monitoring equipment market is crucial for ensuring patient safety and rapid medical response in hospitals, emergency rooms, and ICUs. The demand for these devices is growing due to an aging population, increasing burden of chronic and complex diseases, and hospitals' need for early warning, remote monitoring, and smart care capabilities [6]. - The development of smart monitoring and telemedicine technologies presents new opportunities for medical device manufacturers, allowing for innovation and business model upgrades [6]. - For large medical device companies, establishing robust solutions that integrate monitoring, care, emergency response, and data connectivity is essential for enhancing hospital service capabilities and addressing resource constraints [6]. Business Line Background - In October 2022, Medtronic planned to divest its patient monitoring and respiratory intervention business, valued at $9 billion, attracting interest from potential buyers like GE HealthCare and Carlyle Group. However, by February 2024, the company decided to cancel this divestiture and instead integrate the related business into a new ACM department, focusing on high-growth monitoring technologies [7][9]. - The ACM market has undergone significant changes, particularly with the decline in demand for ventilators post-COVID-19, leading to decreased profitability. Medtronic has consolidated its monitoring technologies, blood oxygen technologies, and respiratory intervention platforms into the new ACM department, which includes products like pulse oximeters and remote patient monitoring solutions [9]. - Medtronic's revenue for fiscal year 2024 was $32.4 billion, with the medical surgical product portfolio (including ACM) accounting for approximately 26%. The ACM department is seen as a growth engine within a $100 billion market potential, particularly in chronic disease management and postoperative care [9]. Appointment Significance - The appointment of Dr. Denny signifies Medtronic's commitment to enhancing clinical value and medical strategy support within its ACM business [14]. - Dr. Denny's extensive clinical and medical affairs experience is expected to improve the alignment of ACM products and technologies with clinical needs, enhancing product design and functionality [17]. - The ACM business is poised for growth due to increasing hospital demand for monitoring and emergency equipment, and Dr. Denny's leadership is anticipated to accelerate new product launches and clinical pathway integration [17]. - Having a seasoned physician and medical manager as CMO is likely to strengthen trust in Medtronic's ACM products among hospitals and clinical institutions, facilitating market expansion and academic collaboration [17]. - In the context of global healthcare resource constraints and rising demands for ICU and emergency capabilities, a focused team on acute care and monitoring is crucial for the company's future competitiveness [17].

科创板风险提示 本次发行股票拟在科创板上市，科创板公司具有研发投入大、经营风 险高、业绩不稳定、退市风险高等特点，投资者面临较大的市场风险。投 资者应充分了解科创板的投资风险及本公司所披露的风险因素，审慎作出 投资决定。 宁波健信超导科技股份有限公司 Ningbo Jansen Superconducting Technologies Co., Ltd. （浙江省慈溪高新技术产业开发区高科大道427号） 首次公开发行股票并在科创板上市 保荐人（主承销商） 招 股 意 向 书 广东省广州市黄埔区中新广州知识城腾飞一街 2 号 618 室 宁波健信超导科技股份有限公司 招股意向书 重要声明 中国证监会、交易所对本次发行所作的任何决定或意见，均不表明其对发 行人注册申请文件及所披露信息的真实性、准确性、完整性作出保证，也不表 明其对发行人的盈利能力、投资价值或者对投资者的收益作出实质性判断或保 证。任何与之相反的声明均属虚假不实陈述。 根据《证券法》规定，股票依法发行后，发行人经营与收益的变化，由发 行人自行负责；投资者自主判断发行人的投资价值，自主作出投资决策，自行 承担股票依法发行后因发行人经营与收益变化或者股 ...

Core Insights - The articles highlight the evolving role of HR in organizations, emphasizing the shift from a reactive support function to a strategic business driver, particularly in the context of AI adoption and workforce management [3][7][11] Group 1: HR Strategies and Trends - The top 10 infographics of 2025 focus on key HR topics, including AI adoption strategies and aligning people with business goals [1] - Coca-Cola's HR strategy transformation involved moving from 32 fragmented units to a networked organization, emphasizing a proactive people strategy that aligns with business objectives [3] - The concept of generative AI (Gen AI) is discussed as both a transformative opportunity and a source of employee anxiety, necessitating open communication forums within organizations [5] Group 2: AI and Workforce Management - The importance of understanding AI's role in HR is underscored, with experts providing guidance on effective AI utilization [4][6] - The three great shifts in HR emphasize the need for HR professionals to transition from being order-takers to architects of the workforce, highlighting the obsolescence of the reactive service-provider model [7] - GE Healthcare's approach to talent management likens effective HR leadership to navigating the sea, requiring adaptability and trend discernment [8] Group 3: Diversity and Generational Management - Strategies for managing a multigenerational workforce are presented, focusing on collaboration and moving beyond stereotypes to meet diverse needs [10] - The discussion on a 4-day workweek raises considerations about its impact on productivity and employee well-being, questioning its suitability for all businesses [12]

Core Insights - BioCardia, Inc. has elected Mr. Marvin Slosman to its Board of Directors effective December 2, 2025, following the departure of Dr. Richard Krasno who completed his term on the same date [1][3]. Group 1: Board Changes - Mr. Marvin Slosman brings extensive expertise in interventional cardiology and a strong track record in advancing medical technologies from concept to commercialization [2]. - Dr. Richard Krasno has been recognized for his significant contributions during his tenure, including guiding the company through key milestones such as the development of clinical evidence for CardiAMP cell therapy and the FDA approval of Morph DNA [3][4]. Group 2: Company Overview - BioCardia is a leader in cellular and cell-derived therapeutics aimed at treating cardiovascular and pulmonary diseases, with its main product platforms being CardiAMP and CardiALLO cell therapies [5]. - The company is currently developing three clinical stage product candidates, supported by its Helix biotherapeutic delivery and Morph vascular navigation product platforms [5].

Core Insights - Boston Scientific (BSX) has been actively pursuing acquisitions to bolster its growth strategy, enhancing its core businesses and entering high-growth adjacent markets [1][5] - The company recently acquired Elutia's BioEnvelope business to prevent post-operative complications for devices like pacemakers and defibrillators, aiming to expand this technology globally [1] - The acquisition of Anrei Medical for approximately $182 million enhances BSX's Endoscopy portfolio, providing more treatment options for physicians [2] - Recent acquisitions, including SoniVie and Intera Oncology, have expanded BSX's offerings in Interventional Cardiology and oncology [3][4] - The acquisition of Bolt Medical aligns with the growth of intravascular lithotripsy therapy, complementing BSX's Cardiovascular portfolio [4] - In Q3 2025, acquisitions contributed 420 basis points to sales, resulting in 15.3% organic revenue growth, exceeding the company's guidance of 12%-14% [5][9] - BSX's stock has increased by 13.1% year-to-date, outperforming the industry growth of 4.9% [8] Acquisitions and Market Position - BSX's recent acquisitions have strengthened its CRM, Endoscopy, Interventional Cardiology, Oncology, and Electrophysiology portfolios [9] - The company has entered into a definitive agreement to acquire Nalu Medical, further enhancing its Neuromodulation division [5][9] - Competitors like Teleflex and GE Healthcare are also active in M&A, with Teleflex acquiring BIOTRONIK's Vascular Intervention business and GE Healthcare acquiring Intelerad for $2.3 billion [6][7] Financial Performance - BSX's valuation is currently high, with a forward five-year Price-to-Earnings (P/E) ratio of 29.57, above its median and industry average [10] - Earnings estimates for BSX are trending upward, with current estimates for the current quarter at $0.78 and for the next year at $3.45 [11][12]

Core Insights - Artificial intelligence (AI) is becoming essential in mammography, with the global AI in breast imaging market projected to grow at a CAGR of 3.30% through 2034, driven by increasing breast cancer prevalence and technological advancements [1] Company Developments - Hologic is committed to advancing technologies in breast health, with real-world studies being crucial for its development [1] - At the upcoming RSNA 2025 Annual Meeting, Hologic will present new data on its breast cancer detection technologies, including the 3DQuorum imaging technology that utilizes AI to optimize the review process for radiologists [2] - A retrospective study involving over 160,000 screening mammography exams indicated that the adoption of 3DQuorum did not significantly alter cancer detection rates, suggesting its potential to enhance workflow efficiency for radiologists [3] - In a separate study, Hologic's Genius AI Detection solution performed comparably to radiologists in detecting challenging breast cancer cases, although it exhibited lower specificity, leading to more false positives [4] - Hologic plans to showcase its AI-powered Genius AI Detection suite, advanced breast surgery technologies, and the next-generation Envision Mammography Platform at RSNA, with the latter set to launch commercially in fiscal 2026 [5] Industry Context - QIAGEN N.V. introduced the QIAsymphony Connect, enhancing its automated nucleic acid purification platform to support liquid biopsy applications [6] - GE Healthcare launched the Genesis Radiology Workspace, aimed at transforming radiology workflows and improving efficiency for radiologists [7] Stock Performance and Valuation - Year-to-date, Hologic shares have increased by 3.8%, compared to the industry's growth of 4.5% [8] - Hologic's forward five-year price-to-sales (P/S) ratio stands at 3.86X, which is lower than the industry average of 4.40X [10]